|
Jan 8
|
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
|
|
Dec 11
|
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
|
|
Dec 11
|
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
|
|
Dec 4
|
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
|
|
Nov 14
|
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
|
|
Nov 9
|
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
|
|
Nov 7
|
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
|
|
Nov 3
|
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
|
|
Nov 2
|
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
|
|
Nov 1
|
Affimed to Participate in Upcoming Investor Conferences
|
|
Jun 22
|
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
|
|
Apr 26
|
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
|